Monte Rosa Therapeutics I... (GLUE)
5.61
0.11 (2.00%)
At close: Mar 03, 2025, 12:18 PM
Monte Rosa Therapeutics Balance Sheet Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 |
| Cash & Equivalents | 128.1M | 54.91M | 346.07M | 41.7M | 6M |
| Short-Term Investments | 104.31M | 207.91M | n/a | n/a | n/a |
| Long-Term Investments | n/a | 4.32M | 5.34M | 1.16M | n/a |
| Other Long-Term Assets | 4.93M | 278K | n/a | n/a | n/a |
| Receivables | 505K | 7.66M | n/a | n/a | n/a |
| Inventory | n/a | 960K | n/a | n/a | n/a |
| Other Current Assets | 3.29M | 5.4M | 5.19M | 1.79M | 3.76M |
| Total Current Assets | 236.21M | 275.89M | 348.67M | 43.59M | 9.76M |
| Property-Plant & Equipment | 62.61M | 61.91M | 12.32M | 4.62M | 1.33M |
| Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a |
| Total Long-Term Assets | 67.54M | 66.5M | 17.66M | 5.79M | 1.33M |
| Total Assets | 303.75M | 342.39M | 366.33M | 49.38M | 11.09M |
| Account Payables | 11.15M | 7.86M | 6.56M | 7.07M | 3.19M |
| Deferred Revenue | 17.68M | n/a | n/a | n/a | n/a |
| Short-Term Debt | 3.16M | 6.25M | n/a | n/a | 750K |
| Other Current Liabilities | 14.6M | 11.45M | 10.08M | 22.21M | 347K |
| Total Current Liabilities | 46.59M | 25.57M | 16.64M | 29.27M | 4.29M |
| Long-Term Debt | 42.88M | 43.87M | n/a | 67.76M | n/a |
| Other Long-Term Liabilities | 2.71M | 1.53M | 2.18M | n/a | n/a |
| Total Long-Term Liabilities | 77.91M | 45.41M | 2.18M | 68.83M | 18.95M |
| Total Liabilities | 124.5M | 70.98M | 18.81M | 98.11M | 23.24M |
| Total Debt | 46.04M | 47M | n/a | 67.76M | 750K |
| Common Stock | 5K | 5K | 5K | 1K | 50K |
| Retained Earnings | -365.89M | -230.54M | -122.03M | -48.08M | -12.2M |
| Comprehensive Income | -2.72M | -1.75M | -2.02M | -1.06M | -68.95K |
| Shareholders Equity | 179.25M | 271.41M | 347.51M | -48.73M | -12.15M |
| Total Investments | 104.31M | 207.91M | 5.34M | 1.16M | n/a |